Modern principles in the management of nodular lymphocyte‐predominant Hodgkin lymphoma
- 28 November 2018
- journal article
- review article
- Published by Wiley in British Journal of Haematology
- Vol. 184 (1), 17-29
- https://doi.org/10.1111/bjh.15616
Abstract
Nodular lymphocyte‐predominant Hodgkin lymphoma (NLPHL) is a unique rare subtype of Hodgkin lymphoma (HL) which differs clinically, pathologically and biologically from classic HL, warranting a nuanced approach to treatment. CD20 expression by malignant lymphocyte‐predominant cells, a tendency for late relapses, and the risk of transformation to aggressive large B‐cell lymphoma are characteristic features with important implications for treatment and follow‐up. Recognition of histopathological variant patterns is also critical, with important implications for prognosis and treatment. The optimal management for NLPHL is unclear and opinions differ as to whether treatment paradigms should be similar to, or differ from, those for classic HL. Therapy differs for early versus advanced stage disease and for frontline versus relapsed or refractory disease. Potential treatment strategies include radiotherapy, combined modality therapy, chemotherapy, rituximab and watchful waiting. Given the excellent overall survival of NLPHL, treatment choices should be geared towards reducing long‐term toxicity and optimizing survivorship. In this review, we provide an overview of the current literature and discuss modern principles in the management of NLPHL.This publication has 60 references indexed in Scilit:
- Nodular Lymphocyte Predominant Hodgkin Lymphoma and T Cell/Histiocyte Rich Large B Cell Lymphoma - Endpoints of a Spectrum of One Disease?PLOS ONE, 2013
- Lenalidomide in patients with refractory or multiple relapsed Hodgkin lymphomaBritish Journal of Haematology, 2010
- Nodular, lymphocyte‐predominant Hodgkin lymphomaCancer, 2009
- Origin and pathogenesis of nodular lymphocyte–predominant Hodgkin lymphoma as revealed by global gene expression analysisThe Journal of Experimental Medicine, 2008
- Lymphocyte-Predominant and Classical Hodgkin's Lymphoma: A Comprehensive Analysis From the German Hodgkin Study GroupJournal of Clinical Oncology, 2008
- 18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin's diseaseHaematologica, 2008
- Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG)Blood, 2008
- Resection alone in 58 children with limited stage, lymphocyte‐predominant Hodgkin lymphoma–experience from the European network group on pediatric Hodgkin lymphomaCancer, 2007
- Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG)Annals of Oncology, 2005
- Long‐term outcome after radiotherapy alone for lymphocyte‐predominant Hodgkin lymphomaCancer, 2005